Comparison of cost-effectiveness of regorafenib and trifluridine/tipiracil combination tablet for treating advanced and recurrent colorectal cancer

  • Authors:
    • Michio Kimura
    • Eiseki Usami
    • Mina Iwai
    • Makiko Go
    • Hitomi Teramachi
    • Tomoaki Yoshimura
  • View Affiliations

  • Published online on: September 15, 2016     https://doi.org/10.3892/mco.2016.1020
  • Pages: 635-640
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Regorafenib and trifluridine/tipiracil combination tablet regimens are standard third‑line or later treatments for advanced and recurrent colorectal cancer with no significant difference in efficacy. The present study aimed to compare the cost-effectiveness of using regorafenib vs. the trifluridine/tipiracil combination tablet. The expected cost was calculated based on data from patients with advanced and recurrent colorectal cancer who were treated with regorafenib or trifluridine/tipiracil combination tablet. The median survival time (MST) from the CORRECT and the RECOURSE study was used to evaluate the therapeutic efficacy of the regimens. The cost‑effectiveness ratio was calculated from the expected cost and MST for the two regimens. The expected cost per patient for the regorafenib and the trifluridine/tipiracil combination tablet regimen was ¥705,330.3 and ¥371,198.7, respectively, and the cost‑effectiveness ratio was ¥110,207.9/MST and ¥52,281.5/MST, respectively. In conclusion, the findings of the present study demonstrated that the trifluridine/tipiracil combination tablet regimen is more cost‑effective compared with the regorafenib regimen.
View Figures
View References

Related Articles

Journal Cover

November 2016
Volume 5 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kimura, M., Usami, E., Iwai, M., Go, M., Teramachi, H., & Yoshimura, T. (2016). Comparison of cost-effectiveness of regorafenib and trifluridine/tipiracil combination tablet for treating advanced and recurrent colorectal cancer. Molecular and Clinical Oncology, 5, 635-640. https://doi.org/10.3892/mco.2016.1020
MLA
Kimura, M., Usami, E., Iwai, M., Go, M., Teramachi, H., Yoshimura, T."Comparison of cost-effectiveness of regorafenib and trifluridine/tipiracil combination tablet for treating advanced and recurrent colorectal cancer". Molecular and Clinical Oncology 5.5 (2016): 635-640.
Chicago
Kimura, M., Usami, E., Iwai, M., Go, M., Teramachi, H., Yoshimura, T."Comparison of cost-effectiveness of regorafenib and trifluridine/tipiracil combination tablet for treating advanced and recurrent colorectal cancer". Molecular and Clinical Oncology 5, no. 5 (2016): 635-640. https://doi.org/10.3892/mco.2016.1020